Immunotherapy of cancer in the era of checkpoint inhibitor

被引：6

作者：

Mehmi, Inderjit ^{[1
]}

Hamid, Omid ^{[1
]}

机构：

[1] Cedar Sinai Affiliate, Angeles Clin & Res Inst, Los Angeles, CA USA

来源：

CLINICAL & EXPERIMENTAL METASTASIS | 2022年 / 39卷 / 01期

关键词：

Melanoma; cSCC; MCC; Immunotherapy; Checkpoint inhibitors; TIM-3; LAG-3; Cytokines; NSCLC; T-CELLS; IPILIMUMAB; PD-1; CHEMOTHERAPY; BLOCKADE;

D O I：

10.1007/s10585-021-10132-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Application of immunotherapy has revolutionized treatment of number of malignancies. We present a review of immunotherapy approaches, early-phase data of number of new immunotherapeutic targets in melanoma, cutaneous squamous cell carcinoma, Merkel cell cancer, and non-small cell lung cancer.

引用

页码：231 / 237

页数：7

共 47 条

[1]

Bodor JN, 2020, 2020 N AM C LUNG CAN

[2] PREVENTION OF T-CELL ANERGY BY SIGNALING THROUGH THE GAMMA(C) CHAIN OF THE IL-2 RECEPTOR [J].

BOUSSIOTIS, VA ;

BARBER, DL ;

NAKARAI, T ;

FREEMAN, GJ ;

GRIBBEN, JG ;

BERNSTEIN, GM ;

DANDREA, AD ;

RITZ, J ;

NADLER, LM .

SCIENCE, 1994, 266 (5187) :1039-1042

[3] PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors [J].

Curran, Michael A. ;

Montalvo, Welby ;

Yagita, Hideo ;

Allison, James P. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (09) :4275-4280

[4] Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma A Preplanned Interim Analysis of a Clinical Trial [J].

D'Angelo, Sandra P. ;

Russell, Jeffery ;

Lebbe, Celeste ;

Chmielowski, Bartosz ;

Gambichler, Thilo ;

Grob, Jean-Jacques ;

Kiecker, Felix ;

Rabinowits, Guilherme ;

Terheyden, Patrick ;

Zwiener, Isabella ;

Bajars, Marcis ;

Hennessy, Meliessa ;

Kaufman, Howard L. .

JAMA ONCOLOGY, 2018, 4 (09)

[5] Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma [J].

Damato, Bertil E. ;

Dukes, Joseph ;

Goodall, Howard ;

Carvajal, Richard D. .

CANCERS, 2019, 11 (07)

[6] Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma [J].

Davar, Diwakar ;

Wang, Hong ;

Chauvin, Joe-Marc ;

Pagliano, Ornella ;

Fourcade, Julien J. ;

Ka, Mignane ;

Menna, Carmine ;

Rose, Amy ;

Sander, Cindy ;

Borhani, Amir A. ;

Karunamurthy, Arivarasan ;

Tarhini, Ahmad A. ;

Tawbi, Hussein A. ;

Zhao, Qing ;

Moreno, Blanca H. ;

Ebbinghaus, Scott ;

Ibrahim, Nageatte ;

Kirkwood, John M. ;

Zarour, Hassane M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (35) :3450-+

[7]

Diab A., 2018, Ann Oncol, V29, pviii442, DOI DOI 10.1093/ANNONC/MDY289.001

[8] Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma. [J].

Eastgate, Melissa A. ;

Atkinson, Victoria ;

Khattak, Muhammad Adnan ;

Roy, Amitesh Chandra ;

Haydon, Andrew Mark ;

Mueller, Christian ;

Dunkelmann, Tina ;

Brignone, Chrystelle ;

Frederic, Triebel .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[9] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[10] Myeloid Cell-Derived Arginase in Cancer Immune Response [J].

Grzywa, Tomasz M. ;

Sosnowska, Anna ;

Matryba, Pawel ;

Rydzynska, Zuzanna ;

Jasinski, Marcin ;

Nowis, Dominika ;

Golab, Jakub .

FRONTIERS IN IMMUNOLOGY, 2020, 11

← 1 2 3 4 5 →